Pramipexole Conversion to Ropinirole Controlled Release (CR)

Completed · Phase 3

Conditions studied: Parkinson Disease

In brief

A conversion study of Mirapex (pramipexole) to Requip (ropinirole) controlled release (CR) in patients with Parkinson's disease to determine the appropriate conversion ratio and side effects related to the drug.

Key facts

Study ID

NCT00275275

Run by

Rajesh Pahwa, MD

People needed

61

Starts

2006-01-01

Expected to finish

2008-05-01

Last updated by the study team

2012-08-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Parkinson Disease
• Currently taking pramipexole
• Never have taken Requip CR

You may not qualify if…

• Can not have significant adverse effects to standard Requip
• Can not have atypical PD due to drugs, metabolic disorders, encephalitis or degenerative diseases
• Can not have unstable medical conditions
• Can not be taking concurrent monoamine oxidase inhibitors except for selegiline (10mg per day or less)
• Female patients of childbearing potential must be using an effective method of contraception.
• Can not be pregnant or lactating.
• This may not be a complete list; there may be additional criteria which may apply.

Where it is running

• University of Kansas Medical Center — Kansas City, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.